Literature DB >> 6860066

[Neuroblastomas treated at the Gustave-Roussy Institute from 1975 to 1979. 173 cases].

O Hartmann, M Scopinaro, M F Tournade, D Sarrazin, J Lemerle.   

Abstract

From 1975 to 1979, 173 children with neuroblastoma were treated according to the same protocol at the Institut Gustave-Roussy. They were classified according to the site of the primary tumor (abdominal: 122; thoracic: 29; others: 22) and according to TNM staging (stage I: 8; stage II: 24; stage III: 35; stage IV: 99; stage V: 2). Depending on stage and age, treatment consisted of surgery and radiotherapy associated with cyclic multiagent chemotherapy (vincristine, Adriamycin, cyclophosphamide). It resulted in a significant improvement of prognosis in stage III patients, especially those with abdominal tumors. In the latter group, prognosis depended mainly on the possibilities of resection of the tumors. Therefore, making these tumors operable remains the major goal of therapy in such patients. Radiotherapy is quite efficient in sterilizing the small post-surgical residual tumors. Prognosis in children over 1 year of age with metastases still remains very poor, even though the quality of the survival is improved.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6860066

Source DB:  PubMed          Journal:  Arch Fr Pediatr        ISSN: 0003-9764


  7 in total

1.  Renal metastases from neuroblastoma. Report of two cases.

Authors:  D Filiatrault; C Hoyoux; P Benoit; L Garel; D Esseltine
Journal:  Pediatr Radiol       Date:  1987

2.  Treatment of advanced neuroblastoma with high-dose melphalan and autologous bone marrow transplantation.

Authors:  O Hartmann; C Kalifa; E Benhamou; C Patte; F Flamant; C Jullien; F Beaujean; J Lemerle
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

3.  Effect of bortezomib on human neuroblastoma: analysis of molecular mechanisms involved in cytotoxicity.

Authors:  Valérie Combaret; Sandrine Boyault; Isabelle Iacono; Stéphanie Brejon; Raphaël Rousseau; Alain Puisieux
Journal:  Mol Cancer       Date:  2008-06-05       Impact factor: 27.401

4.  The LMCE5 unselected cohort of 25 children consecutively diagnosed with untreated stage 4 neuroblastoma over 1 year at diagnosis.

Authors:  D Frappaz; D Perol; J Michon; C Berger; C Coze; J L Bernard; J M Zucker; T Philip
Journal:  Br J Cancer       Date:  2002-11-18       Impact factor: 7.640

5.  Unresectable localized neuroblastoma: improved survival after primary chemotherapy including carboplatin-etoposide. Neuroblastoma Study Group of the Société Française d'Oncologie Pédiatrique (SFOP).

Authors:  H Rubie; J Michon; D Plantaz; M C Peyroulet; C Coze; D Frappaz; P Chastagner; M C Baranzelli; F Méchinaud; P Boutard; P Lutz; Y Perel; G Leverger; L de Lumley; F Millot; J L Stéphan; G Margueritte; O Hartmann
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

6.  Double megatherapy and autologous bone marrow transplantation for advanced neuroblastoma: the LMCE2 study.

Authors:  T Philip; R Ladenstein; J M Zucker; R Pinkerton; E Bouffet; D Louis; W Siegert; J L Bernard; D Frappaz; C Coze
Journal:  Br J Cancer       Date:  1993-01       Impact factor: 7.640

7.  Localised and unresectable neuroblastoma in infants: excellent outcome with low-dose primary chemotherapy.

Authors:  H Rubie; C Coze; D Plantaz; C Munzer; A S Defachelles; C Bergeron; C Thomas; P Chastagner; D Valteau-Couanet; J Michon; V Mosseri; O Hartmann
Journal:  Br J Cancer       Date:  2003-11-03       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.